Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions

Chief Financial Officer of Singular Genomics Systems, Dalen Meeter, reports the acquisition and disposal of common stock and settlement of vested Restricted Stock Units (RSUs).

Summary

• On June 15, 2024, Dalen Meeter, the CFO of Singular Genomics Systems, Inc., engaged in transactions involving the company's stock.
• Meeter acquired 6,250 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Singular Genomics' common stock.
• Following these transactions, Meeter beneficially owns 224,523 shares of common stock, which includes 3,000 shares acquired under the Issuer's employee stock purchase plan.
• Meeter also holds 68,750 Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the CFO, trade in their company's stock. It provides transparency to the market regarding the transactions of company leadership.

Stakeholder Impact

• Shareholders are informed about the CFO's stock transactions, providing transparency into insider activity.
• The transactions themselves may have a negligible impact on the stock price due to the relatively small volume.

Key Dates